P3 Health Partners Inc. (PIII) Stock Price & Analysis
P3 Health Partners Inc. (PIII) rose 3.33% to USD 9.62 as of July 25, 2026 at 21:16 UTC, according to Nexqual real-time market data.
PIII last closed at USD 9.31; the session ranged USD 9.19–9.93 on volume of 17,979 shares. Market capitalization is $1.95B, with a 52-week range of USD 1.52–16.89 (NCM). Source: Nexqual, July 25, 2026 at 21:16 UTC.
Key Statistics (as of July 25, 2026 at 21:16 UTC)
| Price | USD 9.62 |
|---|---|
| Change | ▲ 3.33% (up) |
| Previous Close | USD 9.31 |
| Open | USD 9.43 |
| Day Range | USD 9.19 – 9.93 |
| 52-Week Range | USD 1.52 – 16.89 |
| Volume | 17,979 shares |
| Market Cap | $1.95B |
| Exchange | NCM |
Technical Analysis (PIII)
Nexqual's technical model rates PIII "STRONG SELL" based on 0 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 21:16 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 41.65 (neutral) |
| vs SMA50 | Below (USD 11.1) |
| MACD | -0.24 (negative) |
Analyst Ratings (PIII)
Wall Street analysts rate PIII "None" based on 2 analysts, with a mean price target of USD 14 (range USD 14–14), per Nexqual as of July 25, 2026 at 21:16 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 14 |
| High Target | USD 14 |
| Low Target | USD 14 |
| Buy / Hold / Sell | 1 / 1 / 0 |
Earnings (PIII)
| Next Earnings Date | 2026-08-10 |
|---|---|
| Revenue Estimate | $377.80M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.32 vs est -3.51 ▲ beat |
| 2025-12-31 | USD -23.02 vs est -9.47 ▼ miss |
| 2025-09-30 | USD -9.67 vs est -6.04 ▼ miss |
| 2025-06-30 | USD -6.23 vs est -4.3 ▼ miss |
Source: Nexqual, July 25, 2026 at 21:16 UTC.
Financials & Fundamentals (PIII)
| Total Revenue | $1.47B |
|---|---|
| Revenue Growth (YoY) | +3.50% |
| Gross Margin | -0.75% |
| Operating Margin | +2.13% |
| Profit Margin | -8.58% |
| Current Ratio | 0.33 |
| Total Cash | $25.50M |
| Total Debt | $322.67M |
| Free Cash Flow | $-37.75M |
Source: Nexqual, July 25, 2026 at 21:16 UTC.
Financial Health Score (PIII)
Nexqual rates P3 Health Partners Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 21:16 UTC.
| Growth | Weak — Revenue -3% YoY (annual), declining |
|---|---|
| Profitability | Critical — Gross margin -1% |
| Balance Sheet | Mixed — $25M cash vs $323M debt |
| Cash Flow | Weak — FCF negative: -$38M, burning cash |
| Efficiency | Mixed — No data |
Ownership (PIII)
| Insider Ownership | +56.91% |
|---|---|
| Institutional Ownership | +7.79% |
| Shares Outstanding | 3.33M |
| Float | 1.39M |
| Short % of Float | +1.51% |
Source: Nexqual, July 25, 2026 at 21:16 UTC.
Leadership (PIII)
P3 Health Partners Inc. is led by Aric Coffman (age 51), CEO, President & Director, per Nexqual as of July 25, 2026 at 21:16 UTC.
| CEO, President & Director | Aric Coffman (age 51) |
|---|---|
| Co-Founder, Chief Medical Officer & Director | Amir Bacchus (age 60) |
| Chief Financial Officer | Leif Pedersen (age 49) |
| Executive VP & COO | William Bettermann |
| Senior Vice President of Technology | Devery Goodey |
Major Backers & Investors (PIII)
Notable institutional backers of P3 Health Partners Inc. include Trinity Financial Advisors LLC, Corient Private Wealth LLC, Nine Masts Capital Ltd., according to Nexqual as of July 25, 2026 at 21:16 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Trinity Financial Advisors LLC | 1.01% |
| Corient Private Wealth LLC | 0.6% |
| Nine Masts Capital Ltd. | 0.54% |
| Abundance Wealth Counselors | 0.48% |
| Fidelity | 0.45% |
| HRT Financial LP | 0.45% |
| Susquehanna International Group, LLP | 0.4% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 4.24% |
| Geode Capital | 0.78% |
| BlackRock | 0.42% |
Source: Nexqual, July 25, 2026 at 21:16 UTC.
From P3 Health Partners Inc.'s Latest SEC 10-K Filing (filed 2026-03-26)
Key Strengths & Strategy (as disclosed to the SEC)
- We have developed proprietary technology and processes that support our operational programs and clinical insights, including our P3 Technology/Health Hub, which is a proprietary system that aids in the aggregation and analysis of third-party data we collect.
- Using our proprietary technology platform for integrated data reporting, physicians can stratify their patient panels based on risk.
- P3 Technology/Health Hub The backbone of our P3 Care Model is our proprietary technology platform—P3 Technology/Health Hub—which enables physicians, care teams, patients and their family members to engage in the care journey.
- We staff dedicated care managers and care navigators to help ensure end-to-end patient care across the full continuum.
Partnerships
- We believe that allowing them to maintain their independence increases their engagement with population health management practices, which is key to transforming the healthcare system. • Limited collaboration between PCPs and payors.
- We are "family" and we take care of each other with the same intensity as we take care of our patients. ◦ Collaboration " We achieve more when we work as one. " ◦ Service: "We serve others with empathy, purpose, and a commitment to excellence." • Passion: Our heart is our patients.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| HCWB | HCW Biologics Inc. | USD 2.5 | ▼ 25.26% |
| SNAL | Snail, Inc. | USD 5.14 | ▲ 5.54% |
| TOI | The Oncology Institute, Inc. | USD 4.98 | ▼ 5.86% |
| ERNA | Ernexa Therapeutics Inc. | USD 3.93 | ▼ 11.69% |
| AKAN | Akanda Corp. | USD 7.73 | ▼ 4.09% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 21:16 UTC. This page is informational and not investment advice.